GHK-Cu — 50mg

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper complex) is an endogenous tripeptide that binds copper(II) ions with high affinity and is present in human plasma at concentrations that decline markedly with age — from roughly 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. This age-related decline has generated significant scientific interest in whether exogenous GHK-Cu supplementation can restore aspects of the cellular environment associated with younger tissue.

What distinguishes GHK-Cu from most research peptides is the breadth of its genomic influence. Microarray and RNA-sequencing studies have mapped its regulatory effect across approximately 4,000 human genes, including upregulation of VEGF, BDNF, and BMP-2 — growth factors central to vascular, neural, and bone remodeling respectively. It also stimulates collagen and elastin synthesis through fibroblast activation, and its copper-chelating properties contribute to antioxidant defense by modulating copper-dependent superoxide dismutase activity.

In controlled human dermal studies, 12-week topical application improved measurable collagen density in 70% of subjects. Beyond skin applications, GHK-Cu has demonstrated accelerated wound contraction and epithelialization in both excisional and incisional models. Its neurotrophic properties — particularly BDNF upregulation — have opened parallel lines of investigation in neurodegeneration and cognitive aging research.